{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:28:08Z","timestamp":1766579288920,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Division of AIDS"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HIV Prevention Trials Network","award":["UM1-AI068619","UM1-AI068613","UM1-AI068617"],"award-info":[{"award-number":["UM1-AI068619","UM1-AI068613","UM1-AI068617"]}]},{"DOI":"10.13039\/100006392","name":"AIDS Clinical Trials Group","doi-asserted-by":"crossref","award":["UM1-AI-068636"],"award-info":[{"award-number":["UM1-AI-068636"]}],"id":[{"id":"10.13039\/100006392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tenofovir disoproxil fumarate-containing pre-exposure prophylaxis (PrEP) has been associated with decreases in bone mineral density (BMD), but the bone effects of other non-tenofovir disoproxil fumarate candidate PrEP regimens are not well described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The HPTN 069\/ACTG A5305 study randomized 406 US cisgender men and transgender women, and 188 cisgender women at risk for HIV infection to one of four double-blinded regimens: (i) maraviroc; (ii) maraviroc + emtricitabine; (iii) maraviroc + tenofovir disoproxil fumarate; or (iv) tenofovir disoproxil fumarate + emtricitabine. BMD was measured in a subset of participants at the lumbar spine (LS) and hip by dual-energy X-ray absorptiometry (DXA) at baseline and 48 weeks. Percentage change in LS and hip BMD was compared between the tenofovir disoproxil fumarate- and non-tenofovir disoproxil fumarate-containing arms by Wilcoxon rank-sum tests and multiple linear regression adjusting for sex, race and baseline BMI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline (n = 307), the median age was 33 years, 56% male and 43% black. At the hip, the median percentage change in BMD at 48 weeks was \u20131.05% in the tenofovir disoproxil fumarate arms and 0.0% in the non-tenofovir disoproxil fumarate arms (between group P = 0.001). No interaction by sex was observed. The median percentage change in LS BMD was not different between arms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tenofovir disoproxil fumarate-containing PrEP was associated with significantly greater bone loss compared with maraviroc \u00b1 emtricitabine PrEP at the hip, but not the LS. The BMD changes at the hip were similar in magnitude in men and women.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab400","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T19:11:38Z","timestamp":1635189098000},"page":"500-506","source":"Crossref","is-referenced-by-count":5,"title":["Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and\/or maraviroc and\/or emtricitabine in US men and women: HPTN 069\/ACTG A5305"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-278X","authenticated-orcid":false,"given":"Todd T.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Yuhas","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Fenway Health, Department of Medicine, Beth Israel Deaconess Medical Center\/Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael J.","family":"Landovitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles, Los Angeles,, CA 90025, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying Q.","family":"Chen","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Klingman","sequence":"additional","affiliation":[{"name":"HIV Research Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wairimu","family":"Chege","sequence":"additional","affiliation":[{"name":"Clinical Prevention Research Branch, Prevention Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marybeth B.","family":"Mccauley","sequence":"additional","affiliation":[{"name":"FHI 360, 1825 Connecticut Avenue NW, Washington, DC 20009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M.","family":"Gulick","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill, Cornell, Medicine, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Wilkin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill, Cornell, Medicine, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"2022050618342618600_dkab400-B1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV preexposure prophylaxis: a review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"key":"2022050618342618600_dkab400-B2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2022050618342618600_dkab400-B3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"2022050618342618600_dkab400-B4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/cix167","article-title":"Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort","volume":"64","author":"Borges","year":"2017","journal-title":"Clin Infect Dis"},{"year":"2011","author":"Mulligan","key":"2022050618342618600_dkab400-B5"},{"key":"2022050618342618600_dkab400-B6","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"2022050618342618600_dkab400-B7","doi-asserted-by":"crossref","first-page":"e90111","DOI":"10.1371\/journal.pone.0090111","article-title":"Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana","volume":"9","author":"Kasonde","year":"2014","journal-title":"PLoS One"},{"key":"2022050618342618600_dkab400-B8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/cid\/ciw765","article-title":"Decline in bone mass with tenofovir disoproxil fumarate\/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis","volume":"64","author":"Havens","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022050618342618600_dkab400-B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"2022050618342618600_dkab400-B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QAI.0000000000001475","article-title":"Recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis","volume":"76","author":"Glidden","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022050618342618600_dkab400-B11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/QAI.0000000000000858","article-title":"Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis","volume":"71","author":"Mirembe","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022050618342618600_dkab400-B12","first-page":"238","article-title":"Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069\/ACTG A5305)","volume":"215","author":"Gulick","year":"2017","journal-title":"J Infect Dis"},{"key":"2022050618342618600_dkab400-B13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.7326\/M17-0520","article-title":"Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: a phase 2 randomized trial","volume":"167","author":"Gulick","year":"2017","journal-title":"Ann Intern Med"},{"key":"2022050618342618600_dkab400-B14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom"},{"key":"2022050618342618600_dkab400-B15","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments","volume":"8","author":"Hendrix","year":"2013","journal-title":"PloS One"},{"key":"2022050618342618600_dkab400-B16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cca.2014.02.008","article-title":"Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS\/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma","volume":"431","author":"Emory","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2022050618342618600_dkab400-B17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"2022050618342618600_dkab400-B18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022050618342618600_dkab400-B19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Mulligan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022050618342618600_dkab400-B20","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"key":"2022050618342618600_dkab400-B21","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1097\/QAD.0000000000001995","article-title":"Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy","volume":"32","author":"Kalayjian","year":"2018","journal-title":"AIDS"},{"key":"2022050618342618600_dkab400-B22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1089\/aid.2018.0297","article-title":"Impact of estimated pre-exposure prophylaxis (PrEP) adherence patterns on bone mineral density in a large PrEP demonstration project","volume":"35","author":"Spinelli","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022050618342618600_dkab400-B23","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/en.2005-0065","article-title":"Functional expression of \u03b2-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts","volume":"146","author":"Yano","year":"2005","journal-title":"Endocrinology"},{"key":"2022050618342618600_dkab400-B24","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"2022050618342618600_dkab400-B25","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/0022034509346230","article-title":"CCR5 down-regulates osteoclast function in orthodontic tooth movement","volume":"88","author":"Andrade","year":"2009","journal-title":"J Dent Res"},{"key":"2022050618342618600_dkab400-B26","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/1521-4141(200208)32:8<2124::AID-IMMU2124>3.0.CO;2-S","article-title":"A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses","volume":"32","author":"Yang","year":"2002","journal-title":"Eur J Immunol"},{"key":"2022050618342618600_dkab400-B27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/art.20850","article-title":"Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5","volume":"52","author":"Vierboom","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022050618342618600_dkab400-B28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/rheumatology\/kei213","article-title":"A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats","volume":"45","author":"Okamoto","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2022050618342618600_dkab400-B29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/cid\/civ455","article-title":"Less bone loss with maraviroc- versus tenofovir-containing antiretroviral therapy in the AIDS clinical trials group A5303 study","volume":"61","author":"Taiwo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022050618342618600_dkab400-B30","doi-asserted-by":"crossref","first-page":"e25252","DOI":"10.1002\/jia2.25252","article-title":"Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017","volume":"22","author":"Coy","year":"2019","journal-title":"J Int AIDS Soc"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/2\/500\/43599880\/dkab400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/2\/500\/43599880\/dkab400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T18:40:51Z","timestamp":1651862451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/2\/500\/6427454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,11,13]]},"published-print":{"date-parts":[[2022,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab400","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,11,13]]}}}